Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows
2024-09-25 06:01
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment
2024-09-24 23:37
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners
2024-09-24 21:00
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery
2024-09-24 20:00
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
2024-09-24 15:30
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
2024-09-23 17:42
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024
2024-09-23 17:40
WuXi Biologics Included in Hang Seng ESG 50 Index
2024-09-23 17:30
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
2024-09-23 15:00
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-21 13:42
European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
2024-09-21 09:00
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting
2024-09-20 20:30
Kangpu Completed Bridging Clinical Study of KPG-818 in China
2024-09-20 20:00
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
2024-09-20 16:28
Frost & Sullivan grants the Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAU
2024-09-19 21:48
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024
2024-09-19 20:30
Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology
2024-09-19 17:28
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
2024-09-19 14:00
MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil
2024-09-19 11:05
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
2024-09-19 09:00
1
11
12
13
14
15
451